Wikipedia

User:Mr. Ibrahem/Lutetium (177Lu) vipivotide tetraxetan

< User:Mr. Ibrahem
Lutetium (177Lu) vipivotide tetraxetan
Clinical data
Trade namesPluvicto
Other names177Lu-PSMA-617, Lutetium Lu 177 vipivotide tetraxetan (USAN US)
License data
Routes of
administration		Intravenous
Drug classRadiopharmaceutical
Legal status
Legal status
Chemical and physical data
3D model (JSmol)
  • [177Lu+3].OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]3CC[C@@H](CNC(=O)CN4CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)[O-])CC4)CC3)C(=O)O)C(=O)O
  • InChI=1S/C49H71N9O16.Lu/c59-40(28-55-17-19-56(29-42(62)63)21-23-58(31-44(66)67)24-22-57(20-18-55)30-43(64)65)51-27-32-8-12-35(13-9-32)45(68)52-39(26-33-10-11-34-5-1-2-6-36(34)25-33)46(69)50-16-4-3-7-37(47(70)71)53-49(74)54-38(48(72)73)14-15-41(60)61;/h1-2,5-6,10-11,25,32,35,37-39H,3-4,7-9,12-24,26-31H2,(H,50,69)(H,51,59)(H,52,68)(H,60,61)(H,62,63)(H,64,65)(H,66,67)(H,70,71)(H,72,73)(H2,53,54,74);/q;+3/p-3/t32-,35-,37-,38-,39-;/m0./s1/i;1+2
  • Key:RSTDSVVLNYFDHY-BGOLSCJMSA-K

Lutetium (177Lu) vipivotide tetraxetan, sold under the brand name Pluvicto, is a radioactive medication used to treat metastatic castration-resistant prostate cancer (mCRPC) that is prostate-specific membrane antigen (PSMA)-positive.[2] It is given by injection into a vein.[4]

Common side effects include tiredness, dry mouth, nausea, low hemoglobin, decreased appetite, and constipation.[2] Other side effects may include radiation exposure, bone marrow suppression, infertility, and kidney problems.[2] Use by males with pregnant partners may harm the baby.[2] Vipivotide tetraxetan binds to PSMA-expressing tumor cells while the attached 177Lu destroys the cells by beta particle radiation.[4]

Lutetium (177Lu) vipivotide tetraxetan was approved for medical use in the United States in 2022.[2] In October 2022, Europe recommended its approval.[5] In the United States it costs about 45,000 USD per dose as of 2022.[6]

References

edit
  1. ^ Advanced Accelerator Applications USA. "Pluvicto Product Monograph" (PDF). The Drug and Health Product Register. Government of Canada. Archived (PDF) from the original on 1 October 2022. Retrieved 12 October 2022.
  2. ^ a b c d e f g h "Pluvicto- lutetium lu 177 vipivotide tetraxetan injection, solution". DailyMed. 23 March 2022. Archived from the original on 5 April 2022. Retrieved 4 April 2022.
  3. ^ "FDA approves Pluvicto for metastatic castration-resistant prostate can". U.S. Food and Drug Administration. 23 March 2022. Archived from the original on 24 March 2022. Retrieved 23 March 2022.   This article incorporates text from this source, which is in the public domain.
  4. ^ a b "Lutetium Lu 177 Vipivotide Tetraxetan (Code C148145)". NCI Thesaurus. 28 February 2022. Archived from the original on 15 April 2022. Retrieved 23 March 2022.   This article incorporates text from this source, which is in the public domain.
  5. ^ "Pluvicto: Pending EC decision - European Medicines Agency". European Medicines Agency. 2022-10-13. Archived from the original on 2022-10-14. Retrieved 2022-10-13.
  6. ^ "Pluvicto Prices, Coupons, Copay & Patient Assistance". Drugs.com. Retrieved 12 December 2022.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Lutetium_(177Lu)_vipivotide_tetraxetan&oldid=1223154873"